C Canale

Università degli Studi di Genova, Genova, Liguria, Italy

Are you C Canale?

Claim your profile

Publications (16)30.64 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: The effect of L-propionylcarnitine on patients with left ventricular dysfunction (EF < 45%) NYHA class II, symptomatic despite therapy with digitalis and diuretics was evaluated in a phase II parallel, double-blind, randomized, placebo-controlled study. Fifty patients (28 men and 22 women) aged 37-70 years received 1.5 g of L-propionylcarnitine or placebo on a random basis as oral treatment for 6 months. At baseline, during a 7 day placebo run-in period, and during the 6-month treatment bicycle exercise test, M-B mode and Doppler echocardiography, and clinical evaluation (clinical score) were repeatedly performed. The analysis of variance for repeated measurements showed a statistically significant difference (P < 0.01) in the mean value of exercise time between the treatments over the period of the study. There was a final increase of 0.36 min in the placebo group, 1.4 min in the treated group and a minor production of lactate during exercise in the treated group. Left ventricular shortening fraction and left ventricular ejection fraction showed a significant increase in the L-propionylcarnitine group (respectively P < 0.01 and P < 0.0001) whereas no difference was apparent in the placebo group. Stroke volume index and cardiac index showed significant increments in the treated group (P < 0.05) and systemic vascular resistance was lowered (P < 0.05). No haemodynamic variations were observed in the placebo group, and the clinical score showed a significant improvement in the L-propionylcarnitine treated group. In conclusion, L-propionylcarnitine treatment was shown to improve patient symptomatology and effort tolerance.
    European Heart Journal 10/1994; 15(9):1267-73. · 14.10 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Amlodipine, a novel dihydropyridine calcium-antagonist, was compared to slow-release nifedipine in a short-term study on 40 patients with mild to moderate essential hypertension, in order to assess the efficacy and tolerability of two different dihydropyridine calcium-antagonists with short and long half-life. After a two-week single-blind placebo period, patients were given, in a randomized sequence, amlodipine (5 or 10 mg/day od, 20 patients) or nifedipine s.r. (20 or 40 mg BID, 20 patients). At the end of treatment (12 weeks) a significant lowering of arterial pressure was obtained after 24h from the administration of amlodipin (-34/-17 mmHg) and after 12h from the administration of nifedipine s.r. (-33/-16 mmHg). Furthermore, with both drugs, no significant changes in heart rate and ECG have been reported. Amlodipine was better tolerated than nifedipine, as shown by the lower incidence of side effects. Therefore amlodipine proved to be an effective and well tolerated drug in the therapy of mild to moderate hypertension.
    La Clinica terapeutica 05/1992; 140(4):383-9. · 0.33 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Patients with symptomatic myocardial ischaemia received amlodipine (once daily) or diltiazem (three times daily) for 10 weeks. Amlodipine and diltiazem showed comparable efficacy in reducing angina attack rates and glyceryl trinitrate consumption. Amlodipine produced a significantly greater reduction in the mean rate pressure product. Both drugs were well tolerated with only mild side effects occurring at the higher doses. In two cases, side effects were also reported at the lower dose of diltiazem (30 mg three times daily); none occurred with the 5-mg daily dose of amlodipine. In the overall clinical assessment, efficacy of amlodipine was considered excellent in 100% of cases as compared with 40% for diltiazem. Amlodipine is clearly effective when administered once daily for the treatment of myocardial ischaemia.
    Postgraduate Medical Journal 02/1991; 67 Suppl 5:S54-6. · 1.61 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The efficacy and safety of amlodipine (5-10 mg once daily) and diltiazem (30-60 mg three times daily) were compared in 40 patients with symptomatic myocardial ischemia. A 2-week placebo run-in period was followed by 10 weeks of open treatment with amlodipine (n = 20) or diltiazem (n = 20). Concomitant treatment with other antianginal drugs (except other calcium antagonists) was permitted throughout the study. The baseline blood pressures were 166/93 and 160/91 mm Hg for the amlodipine group and diltiazem groups, respectively. Amlodipine (mean final daily dose of 9.25 mg) reduced blood pressure by - 27/-11 mm Hg compared with a reduction of - 17/-8 mm Hg for diltiazem (mean final daily dose of 180 mg), with no significant effects on heart rate. A significantly greater reduction in the mean rate-pressure product was observed after amlodipine (-20.8%) when compared with diltiazem (-13.1%) (p < 0.05). Amlodipine reduced the mean weekly angina attacks to zero after 6 weeks of treatment (baseline of 3.4 attacks/week) compared with a reduction from 3.3 to 0.35 attacks/week after 10 weeks of treatment with diltiazem. The amlodipine group had a reduction in mean nitroglycerin consumption from baseline of 1.1 mg/week to zero by week 6, whereas the diltiazem group had reduced mean weekly intake from 0.9 to 0.1 mg at the end of the study. The overall assessment of clinical efficacy was excellent for 100% of amlodipine patients compared with 40% of diltiazem patients. The high-density lipoprotein cholesterol/total cholesterol ratio increased by 15.8% with amlodipine compared to diltiazem, which produced a 4.5% decrease. Amlodipine decreased triglycerides by 7.1% compared to 4.5% with diltiazem. The incidence and severity of side effects was comparable for both treatments. Amlodipine once daily was effective and well tolerated in the treatment of patients with symptomatic myocardial ischemia and was comparable with diltiazem three times daily.
    Journal of Cardiovascular Pharmacology 01/1991; 17 Suppl 1:S57-60. · 2.38 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Forty patients with mild-to-moderate arterial hypertension were randomized for double-blind treatment with ketanserin (20 mg b.i.d.) vs. captopril (25 mg b.i.d.) for fifteen days. Diastolic pressure was normalized (less than 90 mmHg) in 11 out of 20 patients of both groups. Of the 18 patients not responding to monotherapy, 17 were treated for 45 days with a combination of both drugs at the same dosages. Diastolic blood pressure was normalized in 15 out of these 17, and in one patient it was reduced by more than 10%. Thus the success rate of therapy was 94%.
    La Clinica terapeutica 05/1990; 133(1):31-4. · 0.33 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: A group of 30 patients with II-III NYHA class cardiac insufficiency was treated with ibopamine in association with other drugs for a 6-month period. The patients were submitted to a 24-h ambulatory ECG Holter monitoring, chest X-ray, Doppler echocardiography in order to calculate total peripheral vascular resistance. Blood levels of aldosterone and renin-angiotensin activity in plasma were also measured, together with norepinephrine excretion. The measurements and recordings were performed in basal conditions before the trial, and were repeated after the first, second, third and sixth month. Laboratory tests were performed at the baseline and after 6 months. The results showed a significant decline in the number of ventricular and supraventricular ectopic beats after treatment. Heart rate did not change. Cardio-thoracic ratio decreased significantly along with peripheral vascular resistance. A very noticeable decline in all three neurohormonal parameters, i.e. norepinephrine excretion, blood level of aldosterone and renin activity in plasma was observed after 1 month's treatment, and this reduction was still present without any attenuation after 6 months. No significant changes were observed in routine laboratory tests.
    Cardiology 02/1990; 77 Suppl 5:43-8. · 1.52 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: A group of 30 patients with II-III NYHA class cardiac insufficiency was treated with ibopamine in association with other drugs for a 6-month period. The patients were submitted to a 24-h ambulatory ECG Holier monitoring, chest X-ray, Doppler echocardiography in order to calculate total peripheral vascular resistance. Blood levels of aldosterone and renin-angiotensin activity in plasma were also measured, together with norepinephrine excretion. The measurements and recordings were performed in basal conditions before the trial, and were repeated after the first, second, third and sixth month. Laboratory tests were performed at the baseline and after 6 months. The results showed a significant decline in the number of ventricular and supraventricular ectopic beats after treatment. Heart rate did not change. Cardio-thoracic ratio decreased significantly along with peripheral vascular resistance. A very noticeable decline in all three neurohormonal parameters, i.e. norepinephrine excretion, blood level of aldosterone and renin activity in plasma was observed after 1 month’s treatment and this reduction was still present without any attenuation after 6 months. No significant changes were observed in routine laboratory tests.
    Cardiology 01/1990; 77(5):43-48. · 1.52 Impact Factor
  • Cardiovascular system, hypertension, and serotonin antagonists edited by R. Paoletti et al., 01/1990; Kluwer Academic Publisher.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Ibopamine, the di-isobutyric ester of N-methyldopamine, is an orally effective dopamine-related drug. Ibopamine acts mainly through the stimulation of beta 1- and beta 2-adrenergic and dopaminic DA1 and DA2 receptors. Cardiac beta 1 activation may facilitate the occurrence of arrhythmias, by reducing the mean refractory period. The aim of this multicenter investigation was to ascertain whether the administration of ibopamine can induce any rhythm disorder or increase pre-existing arrhythmias. In the first part of the investigation, after a washout period 20 patients were treated randomly under double-blind conditions with ibopamine (100 mg t.i.d.) or placebo for 7 days. In the second part of the study, 25 patients were treated with placebo for 7 days, and then with ibopamine (100 mg t.i.d. and 200 mg t.i.d.) for another two 7-day periods. The results did not show any increase in arrhythmias during the two ibopamine periods, in comparison with the data collected under placebo treatment. Ibopamine did not affect heart rate and blood pressure. The number of SVPBs and VPBs decreased considerably in several patients and also the Lown classification improved after ibopamine treatment, even after the 200 mg t.i.d. dose. It can be concluded that ibopamine does not seem to elicit any significant proarrhythmic property.
    Journal of Cardiovascular Pharmacology 02/1989; 14 Suppl 8:S104-10. · 2.38 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: This randomized, double-blind, placebo-controlled, multicenter trial compared the effects of treatment with ibopamine with those of placebo in patients with severe heart failure who still showed symptoms although they were receiving standard therapy with digitalis and diuretics. The results showed a significant and sustained improvement in exercise tolerance (+70% about in average), clinical condition, and NYHA functional class and a decrease in cardiothoracic ratio and left ventricular end-systolic wall stress in patients treated with ibopamine, digitalis, and diuretics (group 1) compared with patients treated with digitalis, diuretics, and placebo (group 2).
    Journal of Cardiovascular Pharmacology 02/1989; 14 Suppl 8:S83-92. · 2.38 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Sixteen angina patients were submitted to echocardiographic examination during the cold pressor test and during hand grip. Certain left ventricular function echocardiographic parameters were assessed in these subjects and in a further 14 patients presenting negative histories for cardiovascular diseases who represented the control group. Of the two tests associated with echocardiography, the cold pressor test appeared capable of inducing the more evident changes on left ventricular function compared to isometric effort in subjects suffering from ischaemic cardiopathy.
    Minerva cardioangiologica 01/1989; 37(7-8):341-9. · 0.43 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Left ventricular (LV) performance was studied in young patients with severe chronic anemia due to beta-thalassemia major, intermedia, and in healthy control subjects. M-mode echocardiograms were recorded in each patient and semiautomatic computerized analysis of the tracings provided data relating to LV performance. Then a statistical analysis of the difference between each specific thalassemic group and the normal subjects was made using Student's t-test for unpaired data. The study showed that cardiac dysfunction is more serious in major than in intermediate beta thalassemia. A follow-up one year later showed a progressive deterioration of the cardiac indices, in spite of treatment with desferrioxamine. A handgrip test was performed in the follow-up study, which permitted us to distinguish different groups relative to the changes in LV performance indices. Our findings indicate that echocardiography provides a simple noninvasive means for assessing changes in the cardiac structure and function, which should also prove useful in the serial evaluation of patients at risk of developing myocardial iron deposition.
    Clinical Cardiology 09/1988; 11(8):563-71. · 1.83 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The discovery tha carnitine takes an active part in the transportation of long-chain acyl residues across the inner mitochondrial membrane dates back to 1958. It has been shown experimentally tha a reduction in myocardial carnitine content takes place after 15-30 min of ischemia. L-carnitine was administered orally in doses of 3 g/day for 30 days to 16 subjects with effort-induced angina and to 14 healthy subjects. A bicycle ergometer exercise test revealed a 1.5 mm (mean) depression of the ST-T segment in the angina subjects after pharmacological wash-out and a 1 mm depression in the same subjects after carnitine treatment. M-code echocardiography showed positive changes in a number of ventricular function parameters in the angina subjects and also, to a lesser extent, in the healthy controls.
    International journal of clinical pharmacology, therapy, and toxicology 05/1988; 26(4):221-4.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Left ventricular (LV) performance was studied in young patients with severe chronic anemia due to β-thalassemia major, intermedia, and in healthy control subjects. M-mode echocardiograms were recorded in each patient and semiautomatic computerized analysis of the tracings provided data relating to LV performance. Then a statistical analysis of the difference between each specific thalassemic group and the normal subjects was made using Student's t-test for unpaired data. The study showed that cardiac dysfunction is more serious in major than in intermediate β thalassemia. A follow-up one year later showed a progressive deterioration of the cardiac indices, in spite of treatment with desferrioxamine. A handgrip test was performed in the follow-up study, which permitted us to distinguish different groups relative to the changes in LV performance indices. Our findings indicate that echocardiography provides a simple noninvasive means for assessing changes in the cardiac structure and function, which should also prove useful in the serial evaluation of patients at risk of developing myocardial iron deposition.
    Clinical Cardiology 01/1988; 11(8):563-571. · 1.83 Impact Factor
  • Cardiologia (Rome, Italy) 12/1987; 32(11):1303-9.
  • Cardiologia (Rome, Italy) 07/1985; 30(6):419-37.